James Bristol, Ph.D.

Jim joined Frazier Healthcare Partners in 2009, and brings significant experience in drug discovery and development to the Life Sciences team. Jim is closely involved with the sourcing and evaluation of new investment opportunities, and advises multiple portfolio companies on topics ranging from medicinal chemistry and preclinical characterization to IP strategy. He currently serves as a member of the scientific advisory boards of Inipharm and Lengo Therapeutics. Jim served as an independent board member of Frazier portfolio company Ignyta prior to its acquisition by Roche, and has served as a member of the scientific advisory board for Mavupharma (acquired by AbbVie) and multiple other Frazier investments.

Jim spent over 30 years in drug discovery research and development at Schering-Plough, Parke-Davis, and Pfizer. He most recently held the position of Senior Vice President, Worldwide Discovery Research at Pfizer and was responsible for research activities in the United States, United Kingdom, and Japan, involving over 3000 scientists at 7 research laboratory sites. Jim has been involved with the discovery and development of many drugs that have been FDA approved or are currently in clinical development, including Lipitor, Lyrica, and Ibrance.

Jim has also been an Adjunct Professor of Medicinal Chemistry at the University of Michigan, and Editor-in-Chief of the American Chemistry Society (ACS) publication series called Annual Reports in Medicinal Chemistry. Jim’s research in drug discovery programs – related to the treatment of gastrointestinal, central nervous system, and cardiovascular diseases with a focus on mechanistic biochemistry – have been recorded in over 100 publications, abstracts, and patents.

In addition to his role at Frazier, Jim is Chairman of the Board of Directors of Deciphera Pharmaceuticals and a board member of Erasca.

Jim received a Ph.D. in Organic Chemistry from the University of New Hampshire and a B.S. in Chemistry from Bates College. He was an N.I.H. Postdoctoral Research Fellow at the University of Michigan and a postdoctoral Fellow at The Squibb Institute for Medical Research.